R

Remed Co Ltd
KOSDAQ:302550

Watchlist Manager
Remed Co Ltd
KOSDAQ:302550
Watchlist
Price: 3 165 KRW -0.47%
Market Cap: ₩97.8B

Remed Co Ltd
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Remed Co Ltd
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
R
Remed Co Ltd
KOSDAQ:302550
Stock-Based Compensation
₩59.8m
CAGR 3-Years
-10%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
I
I Sens Inc
KOSDAQ:099190
Stock-Based Compensation
₩174.9m
CAGR 3-Years
-49%
CAGR 5-Years
7%
CAGR 10-Years
-1%
C
Classys Inc
KOSDAQ:214150
Stock-Based Compensation
₩1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Won Tech Co Ltd
KOSDAQ:336570
Stock-Based Compensation
₩196m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Viol Co Ltd
KOSDAQ:335890
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Seers Technology Co Ltd
KOSDAQ:458870
Stock-Based Compensation
₩28m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Remed Co Ltd
Glance View

Market Cap
97.8B KRW
Industry
Health Care

REMED Co., Ltd. is engaged in the manufacturing of other medical equipment. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2018-08-14. The firm is involved in the manufacturing and sale of transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, electrosurgical units as well as biosignal and monitoring machines. The pain therapy machines include electromagnetic stimulation machines, extracorporeal shockwave therapy machines and high intensity laser therapy machines, among others. The biosignal and monitoring machines include patient monitors, fetal monitors, electrocardiogram (ECG/EKG) machines, among others. The firm distributes its products within the domestic market and to overseas markets.

Intrinsic Value
2 233.44 KRW
Overvaluation 29%
Intrinsic Value
Price ₩3 165
R

See Also

What is Remed Co Ltd's Stock-Based Compensation?
Stock-Based Compensation
59.8m KRW

Based on the financial report for Dec 31, 2024, Remed Co Ltd's Stock-Based Compensation amounts to 59.8m KRW.

What is Remed Co Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-38%

Over the last year, the Stock-Based Compensation growth was -50%. The average annual Stock-Based Compensation growth rates for Remed Co Ltd have been -10% over the past three years , -38% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett